Canada · Delayed Price · Currency is CAD Telo Genomics Statistics
Total Valuation
Telo Genomics has a market cap or net worth of CAD 6.53 million. The enterprise value is 6.87 million.
| Market Cap | 6.53M |
| Enterprise Value | 6.87M |
Important Dates
The next estimated earnings date is Friday, September 25, 2026.
| Earnings Date | Sep 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Telo Genomics has 100.43 million shares outstanding. The number of shares has increased by 24.37% in one year.
| Current Share Class | 100.43M |
| Shares Outstanding | 100.43M |
| Shares Change (YoY) | +24.37% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.98% |
| Owned by Institutions (%) | 0.10% |
| Float | 97.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -6.73 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.49
| Current Ratio | 0.49 |
| Quick Ratio | 0.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.00 |
| Interest Coverage | -32.06 |
Financial Efficiency
Return on equity (ROE) is -3,055.75% and return on invested capital (ROIC) is -190.94%.
| Return on Equity (ROE) | -3,055.75% |
| Return on Assets (ROA) | -106.93% |
| Return on Invested Capital (ROIC) | -190.94% |
| Return on Capital Employed (ROCE) | 252.87% |
| Weighted Average Cost of Capital (WACC) | 4.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -15,376 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.33% in the last 52 weeks. The beta is 0.11, so Telo Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -13.33% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 57.00 |
| Average Volume (20 Days) | 90,827 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -2.24M |
| Pretax Income | -2.35M |
| Net Income | -2.34M |
| EBITDA | -2.19M |
| EBIT | -2.24M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 975,475 in cash and 1.32 million in debt, with a net cash position of -339,596 or -0.00 per share.
| Cash & Cash Equivalents | 975,475 |
| Total Debt | 1.32M |
| Net Cash | -339,596 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -970,209 |
| Book Value Per Share | -0.01 |
| Working Capital | -1.08M |
Cash Flow
In the last 12 months, operating cash flow was -1.30 million and capital expenditures -18,751, giving a free cash flow of -1.32 million.
| Operating Cash Flow | -1.30M |
| Capital Expenditures | -18,751 |
| Depreciation & Amortization | 54,934 |
| Net Borrowing | n/a |
| Free Cash Flow | -1.32M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Telo Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.37% |
| Shareholder Yield | -24.37% |
| Earnings Yield | -35.78% |
| FCF Yield | -20.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 22, 2019. It was a reverse split with a ratio of 0.2.
| Last Split Date | Nov 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |